Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. More Details
Undervalued with adequate balance sheet.
Share Price & News
How has Nectar Lifesciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NECLIFE's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: NECLIFE exceeded the Indian Pharmaceuticals industry which returned 46.3% over the past year.
Return vs Market: NECLIFE exceeded the Indian Market which returned -0.8% over the past year.
Price Volatility Vs. Market
How volatile is Nectar Lifesciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StDoes Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?
1 month ago | Simply Wall StIf You Had Bought Nectar Lifesciences (NSE:NECLIFE) Stock A Year Ago, You Could Pocket A 47% Gain Today
1 month ago | Simply Wall StThe Nectar Lifesciences (NSE:NECLIFE) Share Price Has Gained 47% And Shareholders Are Hoping For More
Is Nectar Lifesciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NECLIFE (₹20.65) is trading below our estimate of fair value (₹128.25)
Significantly Below Fair Value: NECLIFE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NECLIFE is good value based on its PE Ratio (14.6x) compared to the IN Pharmaceuticals industry average (22x).
PE vs Market: NECLIFE is good value based on its PE Ratio (14.6x) compared to the Indian market (16x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NECLIFE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NECLIFE is good value based on its PB Ratio (0.4x) compared to the IN Pharmaceuticals industry average (2.1x).
How is Nectar Lifesciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nectar Lifesciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether Nectar Lifesciences is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Nectar Lifesciences competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Nectar Lifesciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NECLIFE has high quality earnings.
Growing Profit Margin: NECLIFE's current net profit margins (1.3%) are lower than last year (1.7%).
Past Earnings Growth Analysis
Earnings Trend: NECLIFE's earnings have declined by 9.9% per year over the past 5 years.
Accelerating Growth: NECLIFE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: NECLIFE had negative earnings growth (-33.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.7%).
Return on Equity
High ROE: NECLIFE's Return on Equity (2.8%) is considered low.
How is Nectar Lifesciences's financial position?
Financial Position Analysis
Short Term Liabilities: NECLIFE's short term assets (₹16.2B) exceed its short term liabilities (₹12.5B).
Long Term Liabilities: NECLIFE's short term assets (₹16.2B) exceed its long term liabilities (₹2.5B).
Debt to Equity History and Analysis
Debt Level: NECLIFE's debt to equity ratio (68.5%) is considered high.
Reducing Debt: NECLIFE's debt to equity ratio has reduced from 96.6% to 68.5% over the past 5 years.
Debt Coverage: NECLIFE's debt is well covered by operating cash flow (36.6%).
Interest Coverage: NECLIFE's interest payments on its debt are not well covered by EBIT (1.8x coverage).
What is Nectar Lifesciences's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: NECLIFE's dividend (0.24%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.58%).
High Dividend: NECLIFE's dividend (0.24%) is low compared to the top 25% of dividend payers in the Indian market (2.37%).
Stability and Growth of Payments
Stable Dividend: NECLIFE is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.
Growing Dividend: NECLIFE is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: NECLIFE is not paying a notable dividend for the Indian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NECLIFE's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Sanjiv Goyal (60 yo)
Mr. Sanjiv Goyal has been an Executive Chairman and Managing Director of Nectar Lifesciences Limited since June 1, 2006 and serves as its Executive Director. Mr. Goyal has more than 20 years of experience ...
CEO Compensation Analysis
Compensation vs Market: Sanjiv's total compensation ($USD253.97K) is above average for companies of similar size in the Indian market ($USD48.94K).
Compensation vs Earnings: Sanjiv's compensation has been consistent with company performance over the past year.
|Chairman & MD||25.67yrs||₹18.77m||44.35% |
|Executive Director||6.92yrs||₹9.58m||no data|
|Non-Independent Non-Executive Director||no data||₹30.00k||no data|
|Independent Non-Executive Director||10.08yrs||₹32.00k||no data|
|Independent Non-Executive Director||10.58yrs||₹58.00k||no data|
|Non-Independent Non-executive Director||1.58yrs||₹50.00k||no data|
|Independent Non-Executive Director||1.58yrs||₹30.00k||no data|
|Independent Non-Executive Director||4.75yrs||₹15.00k||no data|
Experienced Board: NECLIFE's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Nectar Lifesciences Limited's company bio, employee growth, exchange listings and data sources
- Name: Nectar Lifesciences Limited
- Ticker: NECLIFE
- Exchange: NSEI
- Founded: 1995
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹4.631b
- Shares outstanding: 224.26m
- Website: https://www.neclife.com
Number of Employees
- Nectar Lifesciences Limited
- Himalaya House
- F-66, 6th Floor
- New Delhi
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|532649||BSE (Mumbai Stock Exchange)||Yes||Equity Shares||IN||INR||Jul 2005|
|NECLIFE||NSEI (National Stock Exchange of India)||Yes||Equity Shares||IN||INR||Jul 2005|
|NECLF||BDL (Bourse de Luxembourg)||GDR EACH REPR 1 ORD INR1 REG'S'||LU||USD||Mar 2010|
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and o ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/24 19:22|
|End of Day Share Price||2020/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.